Skip to main content
. Author manuscript; available in PMC: 2017 Jun 10.
Published in final edited form as: Cell Rep. 2017 Mar 28;18(13):3117–3128. doi: 10.1016/j.celrep.2017.02.070

Figure 5. SMARCAD1 and H3K9me3 changes in Cl-Amidine treatment.

Figure 5

(A) SMARCAD1 ChIP-seq intensities in Cl-Amidine treated (Cl+) and untreated ES cells. (B–F) H3K9me3 ChIP-seq intensities in Cl+ and ES cells in 10,000 random genomic regions (B), OCT4, NANOG, CTCF, H3K4me3, H3K4me3 ChIP-seq peaks (C), H3R26Cit peaks (D), SMARCAD1 peaks (E), and the overlaps of H3R26Cit and SMARCAD1 peaks (F). All peaks were defined by ChIP-seq in ES cells. (G) A genome browser view of H3R26Cit, SMARCAD1, H3K9me3 ChIP-seq in ES cells, H3K9me3 in Smarcad1 KD cells, H3K9me3 in Cl+ ES cells, and IgG ChIP-seq and MNase-seq in ES cells.